FinanceAsianet Newsable
ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’
in5points
Zevra announced that EMA's CHMP adopted a negative opinion on its arimoclomol application for Niemann-Pick disease type C.
ZVRA stock fell 23% following the EU regulatory setback.
Analyst describes the risk as a headwind but not insurmountable.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically